Delivery Order SPE2DB24D2013-SPE2DB26FCGPP
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $7,100.94 on August 4, 2025, for the supply of Briviact 75 mg tablets (60-count packages) under a firm fixed-price contract with no set-aside designation. The award is supported by the Defense Logistics Agency's Medical Supply Chain, a division of the Department of Defense, with an ultimate completion date of August 5, 2025. This delivery order...
- The Defense Logistics Agency awarded a $1,544.72 delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Briviact 100 mg tablets (60 count). This competitively awarded, firm fixed-price contract is scheduled for completion by August 13, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a $5,833.23 delivery order to AmerisourceBergen Drug Corp for 60 tablets of Briviact 50 mg, with an ultimate completion date of August 1, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The work will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $2,786.07 to AmerisourceBergen Drug Corp for Briviact 100 mg tablets (60-count) on June 11, 2025, with an ultimate completion date of June 12, 2025. This firm fixed-price, competitively awarded delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a $3,484.01 delivery order to AmerisourceBergen Drug Corp on October 17, 2025, for the supply of Briviact 75 mg tablets (60-count). The contract utilizes firm fixed pricing with a non-competitive set-aside and is scheduled for completion by October 20, 2025. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance. This delivery order is issued under the company's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 1, 2025, for the supply of Briviact 50 mg tablets (60-count packages) with a ceiling value of $1,859.98. This firm fixed-price delivery order, with an ultimate completion date of May 2, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award was competitively made...
- The Defense Logistics Agency awarded a $3,574.48 delivery order to AmerisourceBergen Drug Corp for 60 tablets of Briviact 100 mg on August 25, 2025, with completion scheduled for August 26, 2025. This non-set-aside contract was awarded on a firm fixed price basis and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,072.23 for Briviact 100 mg tablets (60-count) with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and reflects AmerisourceBergen's role as a critical pharmaceutical supplier within the federal medical procurement system. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Briviact 100 mg tablets (60-count packaging). This competitively awarded, firm fixed-price delivery order has a ceiling value of $1,706.39 and an ultimate completion date of August 15, 2025. The contract is performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a $1,861.34 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Briviact 25 mg tablets (60-count units). This is a firm fixed price, non-set-aside contract with a completion date of September 4, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- SPE2DB24D2013Indefinite Delivery Contract
- SPE2DB24D2013-SPE2DB26FCGPPDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 17, 2025, for the supply of Briviact 75 mg tablets (60-count units) under a firm fixed price contract valued at $2,124.38, with an ultimate completion date of October 20, 2025. This non-set-aside award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime vendor agreement extending through December 2026. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical supplier of pharmaceutical products and medical commodities to federal healthcare systems, including military and veteran healthcare providers. The delivery will be performed at the company's Conshohocken facility. This delivery order exemplifies AmerisourceBergen's role within the DLA's pharmaceutical supply chain, fulfilling specialized medical requirements through open competition on a competitive basis. The company's extensive federal contract portfolio demonstrates its capability to supply a comprehensive range of pharmaceutical products across multiple therapeutic domains, from brand-name and generic medications to specialty treatments and medical supplies. The firm fixed pricing structure and rapid delivery timeline reflect the critical nature of pharmaceutical supply requirements within federal military and healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.1k | 10/17/25 |